{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:16:51Z","timestamp":1788779811249,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19K09292, 22K08985,22K08985"],"award-info":[{"award-number":["19K09292, 22K08985,22K08985"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21K08426"],"award-info":[{"award-number":["21K08426"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pleural mesothelioma (PM) is an uncommon yet deadly cancer linked to asbestos exposure. The lack of effective early diagnosis and treatment leads to reduced life expectancy among patients with PM. This study aims to identify a novel molecular target inhibitor to develop more effective therapeutics for PM. Our drug screening assay showed that the fatty acid synthase (FASN) inhibitor cerulenin demonstrates strong and selective antiproliferative properties against\n                    <jats:italic>NF2\/CDKN2A(p16)<\/jats:italic>\n                    -deficient PM cells, surpassing the effects of C75, cisplatin or pemetrexed. FASN protein is frequently detected in\n                    <jats:italic>NF2\/p16<\/jats:italic>\n                    -deficient PM tumor-derived tissues (15\/15, 100%), but rarely in\n                    <jats:italic>NF2\/p16<\/jats:italic>\n                    -intact PM tumors (8\/25, 32%). Notably, cerulenin administration successfully reduced the growth of\n                    <jats:italic>NF2\/p16<\/jats:italic>\n                    -deficient PM tumors in xenografted mice. Cerulenin inhibits mitochondrial fission by targeting dynamin-related protein 1 (DRP1) in\n                    <jats:italic>NF2\/p16<\/jats:italic>\n                    -deficient cells. Moreover, the disruption of the FASN gene leads to increased ubiquitination of DRP1. These findings suggest that FASN might play a role in the tumorigenesis of PM cells through the regulation of mitochondrial dynamics. This research offers a novel perspective on the potential development of precision medicine for PM.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08481-y","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:14:46Z","timestamp":1772273686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting fatty acid synthase suppresses tumor development in NF2\/CDKN2A-deficient pleural mesothelioma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2165-7565","authenticated-orcid":false,"given":"Sivasundaram","family":"Karnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2921","authenticated-orcid":false,"given":"Akinobu","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-7557","authenticated-orcid":false,"given":"Muhammad Nazmul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Lutfur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-8935","authenticated-orcid":false,"given":"Md","family":"Wahiduzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Towhid Ahmed","family":"Shihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nushrat","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam Quang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-8927","authenticated-orcid":false,"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-2948","authenticated-orcid":false,"given":"Akihito","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Riku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-4905","authenticated-orcid":false,"given":"Hiroyuki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"8481_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227:44\u201358.","journal-title":"J Cell Physiol"},{"key":"8481_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(00)04013-7","volume":"357","author":"I Roushdy-Hammady","year":"2001","unstructured":"Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357:444\u20135.","journal-title":"Lancet"},{"key":"8481_CR3","doi-asserted-by":"crossref","unstructured":"Erratum: Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2020;70:313\u20134.","DOI":"10.3322\/caac.21607"},{"key":"8481_CR4","first-page":"63","volume":"7","author":"SC Patel","year":"2016","unstructured":"Patel SC, Dowell JE. Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016;7:63\u201372.","journal-title":"Lung Cancer (Auckl)"},{"key":"8481_CR5","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.22.02542","volume":"41","author":"NJ Vogelzang","year":"2023","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. J Clin Oncol. 2023;41:2125\u201333.","journal-title":"J Clin Oncol"},{"key":"8481_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/carcin\/18.4.825","volume":"18","author":"H Fung","year":"1997","unstructured":"Fung H, Kow YW, Van Houten B, Mossman BT. Patterns of 8-hydroxydeoxyguanosine formation in DNA and indications of oxidative stress in rat and human pleural mesothelial cells after exposure to crocidolite asbestos. Carcinogenesis. 1997;18:825\u201332.","journal-title":"Carcinogenesis"},{"key":"8481_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413\u20139.","journal-title":"Carcinogenesis"},{"key":"8481_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135.","journal-title":"Nat Genet"},{"key":"8481_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668\u201372.","journal-title":"Nat Genet"},{"key":"8481_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264\u20139.","journal-title":"Cancer Res"},{"key":"8481_CR11","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA. 1995;92:10854\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8481_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/cas.13871","volume":"110","author":"M Wahiduzzaman","year":"2019","unstructured":"Wahiduzzaman M, Karnan S, Ota A, Hanamura I, Murakami H, Inoko A, et al. Establishment and characterization of CRISPR\/Cas9-mediated NF2(-\/-) human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. Cancer Sci. 2019;110:180\u201393.","journal-title":"Cancer Sci"},{"key":"8481_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41420-020-00364-1","volume":"6","author":"S Karnan","year":"2020","unstructured":"Karnan S, Ota A, Murakami H, Rahman ML, Hasan MN, Wahiduzzaman M, et al. Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. Cell Death Discov. 2020;6:127.","journal-title":"Cell Death Discov"},{"key":"8481_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41420-023-01552-5","volume":"9","author":"S Karnan","year":"2023","unstructured":"Karnan S, Ota A, Murakami H, Rahman ML, Wahiduzzaman M, Hasan MN, et al. CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma. Cell Death Discov. 2023;9:257.","journal-title":"Cell Death Discov"},{"key":"8481_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763\u201377.","journal-title":"Nat Rev Cancer"},{"key":"8481_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0899-9007(99)00266-X","volume":"16","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16:202\u20138.","journal-title":"Nutrition"},{"key":"8481_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.biopha.2007.08.020","volume":"61","author":"TS Ho","year":"2007","unstructured":"Ho TS, Ho YP, Wong WY, Chi-Ming Chiu L, Wong YS, Eng-Choon Ooi V. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother. 2007;61:578\u201387.","journal-title":"Biomed Pharmacother"},{"key":"8481_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04262-x","volume":"12","author":"B Schroeder","year":"2021","unstructured":"Schroeder B, Vander Steen T, Espinoza I, Venkatapoorna CMK, Hu Z, Silva FM, et al. Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death Dis. 2021;12:977.","journal-title":"Cell Death Dis"},{"key":"8481_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1550-0","volume":"10","author":"J Fafian-Labora","year":"2019","unstructured":"Fafian-Labora J, Carpintero-Fernandez P, Jordan SJD, Shikh-Bahaei T, Abdullah SM, Mahenthiran M, et al. FASN activity is important for the initial stages of the induction of senescence. Cell Death Dis. 2019;10:318.","journal-title":"Cell Death Dis"},{"key":"8481_CR20","doi-asserted-by":"publisher","first-page":"18891","DOI":"10.18632\/oncotarget.3783","volume":"6","author":"YY Zaytseva","year":"2015","unstructured":"Zaytseva YY, Harris JW, Mitov MI, Kim JT, Butterfield DA, Lee EY, et al. Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration. Oncotarget. 2015;6:18891\u2013904.","journal-title":"Oncotarget"},{"key":"8481_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cac2.12247","volume":"42","author":"D Wu","year":"2022","unstructured":"Wu D, Yang Y, Hou Y, Zhao Z, Liang N, Yuan P, et al. Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1. Cancer Commun. 2022;42:37\u201355.","journal-title":"Cancer Commun"},{"key":"8481_CR22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbabio.2017.01.004","volume":"1858","author":"S Srinivasan","year":"2017","unstructured":"Srinivasan S, Guha M, Kashina A, Avadhani NG. Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection. Biochim Biophys Acta Bioenerg. 2017;1858:602\u201314.","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"8481_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbadis.2005.07.001","volume":"1762","author":"CA Mannella","year":"2006","unstructured":"Mannella CA. The relevance of mitochondrial membrane topology to mitochondrial function. Biochim Biophys Acta. 2006;1762:140\u20137.","journal-title":"Biochim Biophys Acta"},{"key":"8481_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108698","volume":"702","author":"J Johnson","year":"2021","unstructured":"Johnson J, Mercado-Ayon E, Mercado-Ayon Y, Dong YN, Halawani S, Ngaba L, et al. Mitochondrial dysfunction in the development and progression of neurodegenerative diseases. Arch Biochem Biophys. 2021;702:108698.","journal-title":"Arch Biochem Biophys"},{"key":"8481_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/cells10040885","volume":"10","author":"P Portz","year":"2021","unstructured":"Portz P, Lee MK. Changes in Drp1 function and mitochondrial morphology are associated with the alpha-synuclein pathology in a transgenic mouse model of Parkinson\u2019s disease. Cells. 2021;10:885.","journal-title":"Cells"},{"key":"8481_CR26","doi-asserted-by":"publisher","first-page":"111213","DOI":"10.18632\/oncotarget.22740","volume":"8","author":"X Zhan","year":"2017","unstructured":"Zhan X, Yu W, Franqui-Machin R, Bates ML, Nadiminti K, Cao H, et al. Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. Oncotarget. 2017;8:111213\u201324.","journal-title":"Oncotarget"},{"key":"8481_CR27","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cancers13071662","volume":"13","author":"A Ortiz-Ruiz","year":"2021","unstructured":"Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, Garcia-Ortiz A, Valeri A, et al. Myc-related mitochondrial activity as a novel target for multiple myeloma. Cancers (Basel). 2021;13:1662.","journal-title":"Cancers (Basel)"},{"key":"8481_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01872-z","volume":"40","author":"S Lv","year":"2022","unstructured":"Lv S, Zhang Y, Song J, Chen J, Huang B, Luo Y, et al. Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2\/PKM2 pathway. Med Oncol. 2022;40:5.","journal-title":"Med Oncol"},{"key":"8481_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.biopha.2017.10.008","volume":"96","author":"Q Wang","year":"2017","unstructured":"Wang Q, Du X, Zhou B, Li J, Lu W, Chen Q, et al. Mitochondrial dysfunction is responsible for fatty acid synthase inhibition-induced apoptosis in breast cancer cells by PdpaMn. Biomed Pharmacother. 2017;96:396\u2013403.","journal-title":"Biomed Pharmacother"},{"key":"8481_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00432-015-2000-8","volume":"142","author":"L Chang","year":"2016","unstructured":"Chang L, Wu P, Senthilkumar R, Tian X, Liu H, Shen X, et al. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway. J Cancer Res Clin Oncol. 2016;142:59\u201372.","journal-title":"J Cancer Res Clin Oncol"},{"key":"8481_CR31","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/j.1349-7006.2010.01596.x","volume":"101","author":"S Murata","year":"2010","unstructured":"Murata S, Yanagisawa K, Fukunaga K, Oda T, Kobayashi A, Sasaki R, et al. Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci. 2010;101:1861\u20135.","journal-title":"Cancer Sci"},{"key":"8481_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/1535-7163.MCT-09-1061","volume":"9","author":"S Uddin","year":"2010","unstructured":"Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, et al. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther. 2010;9:1244\u201355.","journal-title":"Mol Cancer Ther"},{"key":"8481_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/01635581.2013.748923","volume":"65","author":"PR Deepa","year":"2013","unstructured":"Deepa PR, Vandhana S, Krishnakumar S. Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. Nutr Cancer. 2013;65:311\u20136.","journal-title":"Nutr Cancer"},{"key":"8481_CR34","first-page":"3799","volume":"63","author":"E De Schrijver","year":"2003","unstructured":"De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 2003;63:3799\u2013804.","journal-title":"Cancer Res"},{"key":"8481_CR35","first-page":"153","volume":"7","author":"EW Gabrielson","year":"2001","unstructured":"Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001;7:153\u20137.","journal-title":"Clin Cancer Res"},{"key":"8481_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/sj.cdd.4401055","volume":"9","author":"SJ Heiligtag","year":"2002","unstructured":"Heiligtag SJ, Bredehorst R, David KA. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ. 2002;9:1017\u201325.","journal-title":"Cell Death Differ"},{"key":"8481_CR37","first-page":"1949","volume":"40","author":"NY Jeong","year":"2012","unstructured":"Jeong NY, Yoo YH. Cerulenin-induced apoptosis is mediated by disrupting the interaction between AIF and hexokinase II. Int J Oncol. 2012;40:1949\u201356.","journal-title":"Int J Oncol"},{"key":"8481_CR38","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","volume":"77","author":"DS Stepanova","year":"2017","unstructured":"Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, et al. An essential role for the tumor-suppressor merlin in regulating fatty acid synthesis. Cancer Res. 2017;77:5026\u201338.","journal-title":"Cancer Res"},{"key":"8481_CR39","doi-asserted-by":"publisher","first-page":"9877","DOI":"10.1073\/pnas.1819400116","volume":"116","author":"NG Kim","year":"2019","unstructured":"Kim NG, Gumbiner BM. Cell contact and Nf2\/Merlin-dependent regulation of TEAD palmitoylation and activity. Proc Natl Acad Sci USA. 2019;116:9877\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8481_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2022.11.013","volume":"175","author":"P Sa-Ngiamwibool","year":"2023","unstructured":"Sa-Ngiamwibool P, Hamasaki M, Kinoshita Y, Matsumoto S, Sato A, Tsujimura T, et al. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: a multi-institutional study. Lung Cancer. 2023;175:27\u201335.","journal-title":"Lung Cancer"},{"key":"8481_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2217\/fon.10.11","volume":"6","author":"R Flavin","year":"2010","unstructured":"Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6:551\u201362.","journal-title":"Future Oncol"},{"key":"8481_CR42","first-page":"2523","volume":"27","author":"PL Alo","year":"2007","unstructured":"Alo PL, Amini M, Piro F, Pizzuti L, Sebastiani V, Botti C, et al. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res. 2007;27:2523\u20137.","journal-title":"Anticancer Res"},{"key":"8481_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12029-011-9300-2","volume":"43","author":"M Notarnicola","year":"2012","unstructured":"Notarnicola M, Tutino V, Calvani M, Lorusso D, Guerra V, Caruso MG. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J Gastrointest Cancer. 2012;43:508\u201311.","journal-title":"J Gastrointest Cancer"},{"key":"8481_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0304-3835(01)00464-5","volume":"167","author":"Y Wang","year":"2001","unstructured":"Wang Y, Kuhajda FP, Li JN, Pizer ES, Han WF, Sokoll LJ, et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 2001;167:99\u2013104.","journal-title":"Cancer Lett"},{"key":"8481_CR45","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","volume":"91","author":"FP Kuhajda","year":"1994","unstructured":"Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 1994;91:6379\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8481_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0391-z","volume":"32","author":"Y Cai","year":"2015","unstructured":"Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian X, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol. 2015;32:391.","journal-title":"Med Oncol"},{"key":"8481_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s13402-023-00769-x","volume":"46","author":"L Castagnoli","year":"2023","unstructured":"Castagnoli L, Corso S, Franceschini A, Raimondi A, Bellomo SE, Dugo M, et al. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. Cell Oncol. 2023;46:661\u201376.","journal-title":"Cell Oncol"},{"key":"8481_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/708036","volume":"2012","author":"A Jaggupilli","year":"2012","unstructured":"Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012;2012:708036.","journal-title":"Clin Dev Immunol"},{"key":"8481_CR49","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1021\/bi052186q","volume":"45","author":"A Bentebibel","year":"2006","unstructured":"Bentebibel A, Sebastian D, Herrero L, Lopez-Vinas E, Serra D, Asins G, et al. Novel effect of C75 on carnitine palmitoyltransferase I activity and palmitate oxidation. Biochemistry. 2006;45:4339\u201350.","journal-title":"Biochemistry"},{"key":"8481_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1039\/C3FO60484E","volume":"5","author":"P Li","year":"2014","unstructured":"Li P, Tian W, Wang X, Ma X. Inhibitory effect of desoxyrhaponticin and rhaponticin, two natural stilbene glycosides from the Tibetan nutritional food Rheum tanguticum Maxim. ex Balf., on fatty acid synthase and human breast cancer cells. Food Funct. 2014;5:251\u20136.","journal-title":"Food Funct"},{"key":"8481_CR51","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.18632\/oncotarget.14591","volume":"8","author":"R Wagner","year":"2017","unstructured":"Wagner R, Stubiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, et al. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget. 2017;8:11600\u201313.","journal-title":"Oncotarget"},{"key":"8481_CR52","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1126\/science.283.5407.1493","volume":"283","author":"MP Yaffe","year":"1999","unstructured":"Yaffe MP. The machinery of mitochondrial inheritance and behavior. Science. 1999;283:1493\u20137.","journal-title":"Science"},{"key":"8481_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0962-8924(01)02246-2","volume":"12","author":"JM Shaw","year":"2002","unstructured":"Shaw JM, Nunnari J. Mitochondrial dynamics and division in budding yeast. Trends Cell Biol. 2002;12:178\u201384.","journal-title":"Trends Cell Biol"},{"key":"8481_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1083\/jcb.200211046","volume":"160","author":"H Chen","year":"2003","unstructured":"Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160:189\u2013200.","journal-title":"J Cell Biol"},{"key":"8481_CR55","doi-asserted-by":"publisher","first-page":"15834","DOI":"10.1074\/jbc.M109260200","volume":"277","author":"T Misaka","year":"2002","unstructured":"Misaka T, Miyashita T, Kubo Y. Primary structure of a dynamin-related mouse mitochondrial GTPase and its distribution in brain, subcellular localization, and effect on mitochondrial morphology. J Biol Chem. 2002;277:15834\u201342.","journal-title":"J Biol Chem"},{"key":"8481_CR56","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1091\/mbc.12.8.2245","volume":"12","author":"E Smirnova","year":"2001","unstructured":"Smirnova E, Griparic L, Shurland DL, van der Bliek AM. Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell. 2001;12:2245\u201356.","journal-title":"Mol Biol Cell"},{"key":"8481_CR57","doi-asserted-by":"publisher","first-page":"36373","DOI":"10.1074\/jbc.M303758200","volume":"278","author":"DI James","year":"2003","unstructured":"James DI, Parone PA, Mattenberger Y, Martinou JC. hFis1, a novel component of the mammalian mitochondrial fission machinery. J Biol Chem. 2003;278:36373\u20139.","journal-title":"J Biol Chem"},{"key":"8481_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.849962","volume":"10","author":"DP Boulton","year":"2022","unstructured":"Boulton DP, Caino MC. Mitochondrial fission and fusion in tumor progression to metastasis. Front Cell Dev Biol. 2022;10:849962.","journal-title":"Front Cell Dev Biol"},{"key":"8481_CR59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41420-024-01814-w","volume":"10","author":"S Karnan","year":"2024","unstructured":"Karnan S, Hanamura I, Ota A, Vu LQ, Uchino K, Horio T, et al. ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells. Cell Death Discov. 2024;10:56.","journal-title":"Cell Death Discov"},{"key":"8481_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02248-5","volume":"21","author":"T Sato","year":"2021","unstructured":"Sato T, Nakanishi H, Akao K, Okuda M, Mukai S, Kiyono T, et al. Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively. Cancer Cell Int. 2021;21:546.","journal-title":"Cancer Cell Int"},{"key":"8481_CR61","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"8481_CR62","doi-asserted-by":"publisher","first-page":"e0294146","DOI":"10.1371\/journal.pone.0294146","volume":"18","author":"MN Hasan","year":"2023","unstructured":"Hasan MN, Hyodo T, Biswas M, Rahman ML, Mihara Y, Karnan S, et al. Flow cytometry-based quantification of genome editing efficiency in human cell lines using the L1CAM gene. PLoS One. 2023;18:e0294146.","journal-title":"PLoS One"},{"key":"8481_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41420-021-00446-8","volume":"7","author":"S Karnan","year":"2021","unstructured":"Karnan S, Hanamura I, Ota A, Takasugi S, Nakamura A, Takahashi M, et al. CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia. Cell Death Discov. 2021;7:121.","journal-title":"Cell Death Discov"},{"key":"8481_CR64","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/cas.13013","volume":"107","author":"T Ito","year":"2016","unstructured":"Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 2016;107:1527\u201338.","journal-title":"Cancer Sci"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08481-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:03:16Z","timestamp":1774598596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8481"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08481-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This publication has no conflicts of interest, and there has been no substantial financial support for this work that could have influenced its outcome. The manuscript has been reviewed and endorsed by all named authors, and there are no other individuals who meet the criteria for authorship but are not listed. All authors have consented to the order in which they are listed in the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research conducted adhered to the ethical standards outlined by the Japanese Ministry of Health, Labour, and Welfare. All methods were performed in accordance with the relevant guidelines and regulations. All animal experiments were conducted in accordance with the protocols (approval number-2022-20) approved by the ethical committee of Aichi Medical University and followed established guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"287"}}